Cargando…

Cost-Effectiveness Modelling of Sequential Biologic Strategies for the Treatment of Moderate to Severe Rheumatoid Arthritis in Finland

OBJECTIVE: The main objective was to compare the cost-effectiveness of therapeutic options in moderate or severe rheumatoid arthritis (RA) when a clinical response to a first TNF-blocker, either etanercept (ETA), adalimumab (ADA), or infliximab (INF), is insufficient. METHODS: Effectiveness criteria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puolakka, K, Blåfield, H, Kauppi, M, Luosujärvi, R, Peltomaa, R, Leikola-Pelho, T, Sennfalt, K, Beresniak, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349947/ https://www.ncbi.nlm.nih.gov/pubmed/22582103 http://dx.doi.org/10.2174/1874312901206010038

Ejemplares similares

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
por: Soini, Erkki, et al.
Publicado: (2017)

Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain
por: Beresniak, Ariel, et al.
Publicado: (2011)

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
por: Purmonen, Timo, et al.
Publicado: (2019)

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
por: Rantalaiho, Vappu, et al.
Publicado: (2010)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study
por: Paalanen, Kirsi, et al.
Publicado: (2020)

Erratum to: Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study
por: Paalanen, Kirsi, et al.
Publicado: (2021)

Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers
por: Laine, Juha, et al.
Publicado: (2016)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
por: Purmonen, Timo, et al.
Publicado: (2018)

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial
por: Väänänen, Tuija, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
por: Schweikert, Bernd, et al.
Publicado: (2020)

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
por: Taylor, Peter C., et al.
Publicado: (2023)

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Joensuu, Jaana T., et al.
Publicado: (2015)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Indirect costs of rheumatoid arthritis
por: Raciborski, Filip, et al.
Publicado: (2015)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China
por: Wu, Bin, et al.
Publicado: (2012)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
por: Findeisen, Kate E, et al.
Publicado: (2021)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014
por: Tłustochowicz, Małgorzata, et al.
Publicado: (2016)

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
por: Chastek, Benjamin, et al.
Publicado: (2017)

Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis
por: Hopson, Sari, et al.
Publicado: (2016)

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
por: Rendas-Baum, Regina, et al.
Publicado: (2011)

Incidence of seropositive rheumatoid arthritis in population-based studies in Northern Savo, Finland, during 1980–2020
por: Elfving, Pia, et al.
Publicado: (2023)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Cell biology of synovial inflammation and secondary osteoporosis in rheumatoid arthritis
por: Tanaka, Y, et al.
Publicado: (2003)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania
por: Codreanu, Cătălin, et al.
Publicado: (2019)

The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
por: Scott, David, et al.
Publicado: (2020)

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
por: Agarwal, Sandeep K.
Publicado: (2011)

First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study
por: Muilu, Paula, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ibnicgbhruhl8s2db9c7ou4t47